Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament |
Trials |
|
|
clinical deterioration | clinical improvement | deaths | PCR-negative conversion |
Ad26.COV2.S A EFFACER | 0 | - | - | - | - | |
BBV152 | 0 | - | - | - | - | |
BCG vaccination | 0 | - | - | - | - | |
CureVac | 0 | - | - | - | - | |
DNA vaccine | 0 | - | - | - | - | |
Inactivated virus vaccine | 0 | - | - | - | - | |
Non replicating viral vector | 0 | - | - | - | - | |
protein subunit vaccine | 0 | - | - | - | - | |
RNA vaccine | 0 | - | - | - | - | |
Sanofi/GSK recombinant protein vaccine | 0 | - | - | - | - | |
SCB-2019 | 0 | - | - | - | - | |
virus-like particles vaccine | 0 | - | - | - | - | |
Zy-Cov-D (Zydus Cadila) | 0 | - | - | - | - | |